{Reference Type}: Journal Article
{Title}: Altered expression and localization of nuclear envelope proteins in a prostate cancer cell system.
{Author}: Sandoval A;Garrido E;Camacho J;Magaña JJ;Cisneros B;
{Journal}: Mol Biol Rep
{Volume}: 51
{Issue}: 1
{Year}: 2024 Aug 8
{Factor}: 2.742
{DOI}: 10.1007/s11033-024-09836-4
{Abstract}: <B>BACKGROUND: </B>The nuclear envelope (NE), which is composed of the outer and inner nuclear membranes, the nuclear pore complex and the nuclear lamina, regulates a plethora of cellular processes, including those that restrict cancer development (genomic stability, cell cycle regulation, and cell migration). Thus, impaired NE is functionally related to tumorigenesis, and monitoring of NE alterations is used to diagnose cancer. However, the chronology of NE changes occurring during cancer evolution and the connection between them remained to be precisely defined, due to the lack of appropriate cell models.<BR><B>METHODS: </B>The expression and subcellular localization of NE proteins (lamins A/C and B1 and the inner nuclear membrane proteins emerin and β-dystroglycan [β-DG]) during prostate cancer progression were analyzed, using confocal microscopy and western blot assays, and a prostate cancer cell system comprising RWPE-1 epithelial prostate cells and several prostate cancer cell lines with different invasiveness.<BR><B>RESULTS: </B>Deformed nuclei and the mislocalization and low expression of lamin A/C, lamin B1, and emerin became more prominent as the invasiveness of the prostate cancer lines increased. Suppression of lamin A/C expression was an early event during prostate cancer evolution, while a more extensive deregulation of NE proteins, including β-DG, occurred in metastatic prostate cells.<BR><B>CONCLUSIONS: </B>The RWPE-1 cell line-based system was found to be suitable for the correlation of NE impairment with prostate cancer invasiveness and determination of the chronology of NE alterations during prostate carcinogenesis. Further study of this cell system would help to identify biomarkers for prostate cancer prognosis and diagnosis.